Journal of Antimicrobial Chemotherapy (2000) 45, 729-748
© 2000 The British Society for Antimicrobial Chemotherapy
Working Party Report |
Management of herpes virus infections following transplantation
Introduction
Herpesvirus infections lead to significant morbidity and mortality in transplant recipients.1 Cytomegalovirus (CMV) is the most important virus in this respect, and prevention of CMV disease has been the subject of a large number of clinical trials. In addition, herpes simplex virus (HSV) and varicella zoster virus (VZV) can lead to severe disease. With regard to Epstein–Barr virus (EBV), post-transplant lymphoproliferative disease (PTLD) is increasingly recognized as a major complication. By contrast, disease association with human herpes virus 6 (HHV-6) and human herpes virus 7 (HHV-7) infections following transplantation requires clarification, as does the natural history of these infections. There is little information available on human herpes virus 8 (HHV-8) infection in the transplant scenario.
An increasing number of antiviral agents are available for treatment and prevention of these infections, including acyclovir and its prodrug, valaciclovir; ganciclovir and its prodrug, valganciclovir; foscarnet; famciclovir; adefovir; and cidofovir. In addition, interferons and
Bone marrow transplantation—general aspects
Solid organ transplantation—general aspects
Cytomegalovirus
Management of CMV disease: BMT patients
Treatment
Recommendation.. Prophylaxis
Recommendations.. Pre-emptive therapy
Recommendations.. Management of CMV disease: liver and renal transplantation
Treatment
Recommendations.. Prophylaxis
Recommendation.. Pre-emptive therapy
Recommendation.. Management of CMV disease: thoracic transplants
Treatment
Recommendation.. Prophylaxis
Recommendation.. Pre-emptive therapy
Recommendations.. Future strategies for control of CMV disease in transplantation
Herpes simplex virus
Management of herpes simplex disease: BMT patients
Treatment. Recommendations.
Prophylaxis. Recommendations.
Management of herpes simplex disease: solid organ transplant patients including thoracic transplantation
Treatment
Recommendations.. Prophylaxis
Recommendations.. Varicella-zoster virus
Management of VZV disease: BMT patients
Treatment. Recommendations.
Prophylaxis. Recommendations.
Management of VZV disease: solid organ transplant patients including thoracic transplantation
Treatment
Recommendations.. Prophylaxis
Recommendations.. Epstein–Barr virus
Recommendations.
Other herpes viruses
Conclusions
Notes
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H.-Y. Cheng, C.-M. Yang, T.-C. Lin, L.-T. Lin, L.-C. Chiang, and C.-C. Lin Excoecarianin, Isolated from Phyllanthus urinaria Linnea, Inhibits Herpes Simplex Virus Type 2 Infection through Inactivation of Viral Particles Evid. Based Complement. Altern. Med., October 6, 2009; (2009) nep157v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Cheng, C.-M. Yang, T.-C. Lin, D.-E. Shieh, and C.-C. Lin ent-Epiafzelechin-(4{alpha}->8)-epiafzelechin extracted from Cassia javanica inhibits herpes simplex virus type 2 replication J. Med. Microbiol., February 1, 2006; 55(2): 201 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Cheng, T.-C. Lin, C.-M. Yang, K.-C. Wang, L.-T. Lin, and C.-C. Lin Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage replication of herpes simplex virus type 2 in vitro J. Antimicrob. Chemother., April 1, 2004; 53(4): 577 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Oien, R. J. Brideau, T. A. Hopkins, J. L. Wieber, M. L. Knechtel, J. A. Shelly, R. A. Anstadt, P. A. Wells, R. A. Poorman, A. Huang, et al. Broad-Spectrum Antiherpes Activities of 4-Hydroxyquinoline Carboxamides, a Novel Class of Herpesvirus Polymerase Inhibitors Antimicrob. Agents Chemother., March 1, 2002; 46(3): 724 - 730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. C. Snell New treatments for viral respiratory tract infections--opportunities and problems J. Antimicrob. Chemother., March 1, 2001; 47(3): 251 - 259. [Full Text] [PDF]
|
|